PURE Bioscience, Inc. (PURE)
OTCMKTS · Delayed Price · Currency is USD
0.0600
0.00 (0.00%)
Aug 25, 2026, 4:00 PM EST
PURE Bioscience Balance Sheet
Financials in millions USD. Fiscal year is August - July.
Millions USD. Fiscal year is Aug - Jul.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 30, 2026 | Jul '25 Jul 31, 2025 | Jul '24 Jul 31, 2024 | Jul '23 Jul 31, 2023 | Jul '22 Jul 31, 2022 | Jul '21 Jul 31, 2021 |
Cash & Equivalents | 0.98 | 0.33 | 0.35 | 1.1 | 3.39 | 2.39 |
Cash & Short-Term Investments | 0.98 | 0.33 | 0.35 | 1.1 | 3.39 | 2.39 |
Cash Growth | 82.04% | -4.30% | -68.13% | -67.71% | 41.88% | -37.74% |
Receivables | 0.24 | 0.47 | 0.3 | 0.29 | 0.2 | 0.37 |
Inventory | 0.23 | 0.14 | 0.06 | 0.09 | 0.18 | 0.33 |
Prepaid Expenses | 0.02 | 0.02 | 0.03 | 0.06 | 0.02 | 0.03 |
Restricted Cash | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 |
Total Current Assets | 1.55 | 1.05 | 0.81 | 1.6 | 3.86 | 3.2 |
Property, Plant & Equipment | 0.01 | 0.01 | 0.01 | 0.22 | 0.62 | 0.74 |
Other Intangible Assets | - | - | - | - | - | 0.37 |
Total Assets | 1.56 | 1.06 | 0.82 | 1.83 | 4.48 | 4.3 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 30, 2026 | Jul '25 Jul 31, 2025 | Jul '24 Jul 31, 2024 | Jul '23 Jul 31, 2023 | Jul '22 Jul 31, 2022 | Jul '21 Jul 31, 2021 |
Accounts Payable | 0.72 | 0.78 | 0.6 | 0.42 | 0.49 | 0.59 |
Accrued Expenses | 0.18 | 0.15 | 0.13 | 0.11 | 0.09 | 0.14 |
Short-Term Debt | - | - | - | - | - | 0.24 |
Total Current Liabilities | 3.65 | 0.94 | 0.73 | 0.53 | 0.58 | 0.97 |
Long-Term Debt | 3.74 | 5.24 | 2.95 | 1.02 | - | - |
Total Liabilities | 7.4 | 6.17 | 3.68 | 1.55 | 0.58 | 0.97 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 30, 2026 | Jul '25 Jul 31, 2025 | Jul '24 Jul 31, 2024 | Jul '23 Jul 31, 2023 | Jul '22 Jul 31, 2022 | Jul '21 Jul 31, 2021 |
Common Stock | 1.3 | 1.12 | 1.12 | 1.12 | 1.11 | 0.87 |
Additional Paid-In Capital | 133.73 | 132.76 | 132.61 | 132.4 | 132.08 | 128.25 |
Retained Earnings | -140.87 | -138.99 | -136.6 | -133.25 | -129.28 | -125.79 |
Shareholders' Equity | -5.84 | -5.12 | -2.86 | 0.27 | 3.91 | 3.33 |
Total Liabilities & Equity | 1.56 | 1.06 | 0.82 | 1.83 | 4.48 | 4.3 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 30, 2026 | Jul '25 Jul 31, 2025 | Jul '24 Jul 31, 2024 | Jul '23 Jul 31, 2023 | Jul '22 Jul 31, 2022 | Jul '21 Jul 31, 2021 |
Total Debt | 6.5 | 5.24 | 2.95 | 1.02 | - | 0.24 |
Net Cash (Debt) | -5.51 | -4.9 | -2.6 | 0.07 | 3.39 | 2.15 |
Net Cash Growth | - | - | - | -97.82% | 57.65% | -43.97% |
Net Cash Per Share | -0.05 | -0.04 | -0.02 | 0.00 | 0.04 | 0.02 |
Filing Date Shares Outstanding | 130.02 | 111.89 | 111.86 | 111.86 | 111.36 | 87.22 |
Total Common Shares Outstanding | 130.02 | 111.89 | 111.86 | 111.86 | 111.36 | 87.22 |
Working Capital | -2.11 | 0.11 | 0.07 | 1.07 | 3.29 | 2.23 |
Book Value Per Share | -0.04 | -0.05 | -0.03 | 0.00 | 0.04 | 0.04 |
Tangible Book Value | -5.84 | -5.12 | -2.86 | 0.27 | 3.91 | 2.97 |
Tangible Book Value Per Share | -0.04 | -0.05 | -0.03 | 0.00 | 0.04 | 0.03 |
Machinery | - | 1.62 | 1.62 | 1.62 | 1.58 | 1.52 |
Construction In Progress | - | - | - | - | 0.08 | 0.06 |